ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1393

Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials

Roy Fleischmann1, Zoltán Szekanecz2, Eduardo Mysler3, Kevin Winthrop4, Kunihiro Yamaoka5, Kirsten Famulla6, Yanna Song7, Birgit Kovacs7, Sander Strengholt8 and Gerd Burmester9, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Debrecen, Debrecen, Hungary, 3Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, 4School of Medicine, Oregon Health and Science University, Portland, OR, 5Kitasato University School of Medicine, Sagamihara, Japan, 6AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, 7AbbVie, North Chicago, IL, 8AbbVie Inc., North Chicago, IL, 9Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, clinical trial, Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited data are available evaluating  whether effective disease control reduces the risk of AE development. This post hoc analysis assesses the relationship between disease activity and development of significant AEs in RA patients treated with the JAK inhibitor upadacitinib (UPA) 15 mg in the SELECT phase 3 program.

Methods: This post hoc analysis of data from six UPA phase 3 trials included patients randomized to UPA 15 mg once daily and those who switched from placebo, MTX, or adalimumab to UPA 15 mg. Data were analyzed up to ~5 years (week 260; except for data from SELECT-CHOICE, which was analyzed to the final patient visit at 4.2 years [week 216]). All patients who received at least one dose of UPA 15 mg and had a CDAI score >10 at the time of UPA initiation were included. Cox regression analysis was performed for each AE of interest using time-dependent variables (CDAI categories or hsCRP per 5 mg/L increment) along with pre-specified covariates based on the literature (Table 1). CDAI categories were remission (CDAI ≤2.8), low ( >2.8–≤10), moderate ( >10–≤22), or high ( >22) disease activity (LDA, MDA, and HDA, respectively). Analysis of covariance (ANCOVA) was used to compare the cumulative time-weighted average CDAI between patients with or without AE occurrence. All P values are nominal.

Results: A total of 2623 UPA 15 mg-treated patients were included in this analysis. At 4.2 years, which is the latest date at which data was available from all 6 trials, 43% (n=723), 40% (n=660), 14% (n=240), and 3% (n=43) were in CDAI remission, LDA, MDA, and HDA, respectively. Cox regression analysis showed that patients in CDAI HDA had a ~5-fold greater likelihood of MACE or VTE than those in remission over a 5-year period (hazard ratios [95% CI]: MACE, 4.5 [1.3, 15.4], P< .05; VTE, 5.7 [1.8, 18.2], P<.01) (Figure 1). In addition, patients with active disease trended toward a higher risk of developing MACE and VTE versus patients in remission. Residual disease activity also significantly increased the probability of developing SIE, but no relationship was observed for herpes zoster or malignancy. Additionally, 5 mg/L elevation in hsCRP increased the risk of MACE, VTE, and SIE by 7.1%–7.5% and increased the risk of herpes zoster by 4.4%  (Figure 2). In analyses based on the time-weighted average disease activity, mean CDAI scores were 4.2 units higher in patients who experienced VTE than those who did not (P< .05). Comparisons of average CDAI between patients with/without other examined AEs were not statistically different, although patients with MACE had numerically higher average disease activity than those who did not (mean CDAI difference: 3.1 units).

Conclusion: In patients receiving UPA 15 mg in the SELECT RA program, decreased risk of MACE, VTE, and SIE were observed in patients in remission versus those with high disease activity levels. Overall, our findings support the importance of remission and inflammation reduction in mitigating the risk of some AEs, although results should be interpreted with caution due to the limited number of events. 

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: R. Fleischmann: AbbVie, 2, 5, Amgen, 2, 5, Arthrosi, 2, 5, AstraZeneca, 2, 5, Biogen, 2, 5, BMS, 2, 5, Boehringer-Ingelheim, 2, 5, Cyxone, 2, 5, Dren Bio, 2, 5, Flexion, 2, 5, Galapagos, 2, 5, Galvani, 2, 5, Genentech, 2, 5, Gilead, 2, 5, GSK, 2, 5, ImmuneMed, 2, 5, Immunovant, 2, 5, InventisBio, 2, 5, Janssen, 2, 5, Kinska, 2, 5, Lilly, 2, 5, Monte Rosa, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Priovant, 2, 5, Recor, 2, 5, Roche, 2, 5, Sanofi-Aventis, 2, 5, Vyne, 2, 5; Z. Szekanecz: AbbVie, 2, Boehringer Ingelheim, 2, Gedeon Richter, 2, Lilly, 2, MSD, 2, Novartis, 2, Pfizer, 2, 5, Roche, 2; E. Mysler: AbbVie, 2, 5, Alpine Immunology, 2, 5, Amgen, 2, 5, Astra Zeneca, 2, 5, BMS, 2, 5, GSK, 2, 5, HiBio, 2, 5, Janssen, 2, 2, 5, 5, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 2, 5, Sanofi, 2, 5; K. Winthrop: AbbVie, 2, AstraZeneca, 2, BMS, 2, 5, Galapagos, 2, Gilead, 2, GSK, 2, Lilly, 2, Novartis, 2, Pfizer, 2, 5, Regeneron, 2, Roche, 2, Sanofi, 2, UCB, 2; K. Yamaoka: AbbVie, 6, Astellas, 6, BMS, 6, Chugai, 6, GK, 6, Mitsubishi-Tanabe, 6, Pfizer, 6, Takeda, 6; K. Famulla: AbbVie, 3, 11; Y. Song: AbbVie, 3, 11; B. Kovacs: AbbVie, 3, 11; S. Strengholt: AbbVie, 3, 11; G. Burmester: AbbVie, 2, Amgen, 2, BMS, 2, Galapagos, 2, Lilly, 2, MSD, 2, Pfizer, 2, Sanofi, 2.

To cite this abstract in AMA style:

Fleischmann R, Szekanecz Z, Mysler E, Winthrop K, Yamaoka K, Famulla K, Song Y, Kovacs B, Strengholt S, Burmester G. Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/relationship-between-disease-activity-and-adverse-events-in-rheumatoid-arthritis-an-integrated-post-hoc-analysis-of-upadacitinib-phase-3-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-disease-activity-and-adverse-events-in-rheumatoid-arthritis-an-integrated-post-hoc-analysis-of-upadacitinib-phase-3-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology